Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Jul;346(1):11–22. doi: 10.1124/jpet.113.203984

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics

PMC Copyright notice

Fig. 8. — Development of tolerance to the antiallodynic effects of repeated intrathecal administration of SR16435 (3 µg) or buprenorphine (3 µg) in mice with neuropathic pain. (A) Changes in SR16435 and buprenorphine-induced increase in paw withdrawal thresholds (g). (B) Changes in SR16435- and buprenorphine-induced percentage of maximum possible antiallodynic effects. Mice were tested each day at 0.5 hours after the drug administration. ▪ is SR16435; ● is buprenorphine. #Statistically significant difference from the antiallodynic effects of SR16435 on day 1 of the treatment. *Statistically difference from the antiallodynic effects of buprenorphine on day 1 (P < 0.05).